Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of “Buy” by Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $23.00.

A number of equities research analysts recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, February 18th. Chardan Capital restated a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, February 19th. HC Wainwright increased their price target on Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th.

Stoke Therapeutics Stock Down 5.7 %

Shares of Stoke Therapeutics stock opened at $7.40 on Tuesday. Stoke Therapeutics has a 12-month low of $5.60 and a 12-month high of $17.58. The stock has a market cap of $391.96 million, a P/E ratio of -3.52 and a beta of 0.95. The business’s 50 day moving average is $10.11 and its 200-day moving average is $12.00.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,666 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the transaction, the general counsel now directly owns 21,476 shares of the company’s stock, valued at $292,288.36. This represents a 38.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,170 shares of the company’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the transaction, the chief executive officer now directly owns 68,671 shares in the company, valued at approximately $877,615.38. This represents a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 52,849 shares of company stock valued at $688,721 in the last ninety days. 11.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

Several large investors have recently modified their holdings of STOK. Mesirow Financial Investment Management Inc. acquired a new stake in shares of Stoke Therapeutics during the 3rd quarter worth $192,000. Los Angeles Capital Management LLC grew its holdings in shares of Stoke Therapeutics by 54.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock worth $1,266,000 after purchasing an additional 36,240 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Stoke Therapeutics during the 3rd quarter worth $160,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Stoke Therapeutics by 9.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company’s stock worth $3,885,000 after purchasing an additional 26,870 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after purchasing an additional 71,647 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.